Skip to main
CING

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate is a clinical stage biopharmaceutical company with a strong focus on developing treatments for ADHD and anxiety using its proprietary drug delivery platform technology. The recent $12 million raise puts the company in a comfortable cash position to fund its operations into mid-2027, providing a stable financial outlook. With a current valuation that we believe to be very attractive, coupled with positive results from its recent reports, we maintain a BUY rating for this company with a 12-month price target of $58, taking into account risks such as liquidity, product efficacy, and regulatory approvals.

Bears say

Cingulate is experiencing significant leadership changes, with the CEO being placed on administrative leave and returning after resolving personal issues, which may negatively impact operations. While the company's focus on using its Precision Timed Release (PTR) drug delivery platform to develop once-daily, multi-dose tablets for ADHD and anxiety has potential, it faces competition from already established approved drugs, and it remains to be seen if the platform can deliver on its promise of improved patient outcomes. Additionally, the lack of diversification in the company's pipeline may pose a risk to its long-term success.

Cingulate (CING) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $34.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $34.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.